572 related articles for article (PubMed ID: 27149976)
1. Effect of non-invasive prenatal testing as a contingent approach on the indications for invasive prenatal diagnosis and prenatal detection rate of Down's syndrome.
Kou KO; Poon CF; Kwok SL; Chan KY; Tang MH; Kan AS; Leung KY
Hong Kong Med J; 2016 Jun; 22(3):223-30. PubMed ID: 27149976
[TBL] [Abstract][Full Text] [Related]
2. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
3. A prospective clinical trial to compare the performance of dried blood spots prenatal screening for Down's syndrome with conventional non-invasive testing technology.
Hu H; Jiang Y; Zhang M; Liu S; Hao N; Zhou J; Liu J; Zhang X; Ma L
Exp Biol Med (Maywood); 2017 Mar; 242(5):547-553. PubMed ID: 28056555
[TBL] [Abstract][Full Text] [Related]
4. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
Wald NJ; Watt HC; Hackshaw AK
N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
[TBL] [Abstract][Full Text] [Related]
5. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
[TBL] [Abstract][Full Text] [Related]
6. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
[TBL] [Abstract][Full Text] [Related]
7. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.
Chitty LS; Wright D; Hill M; Verhoef TI; Daley R; Lewis C; Mason S; McKay F; Jenkins L; Howarth A; Cameron L; McEwan A; Fisher J; Kroese M; Morris S
BMJ; 2016 Jul; 354():i3426. PubMed ID: 27378786
[TBL] [Abstract][Full Text] [Related]
8. Importance of the integrated test in the Down's syndrome screening algorithm.
Springer D; Loucky J; Tesner P; Cutka D; Stejskal D; Gregor V; Zima T
J Med Screen; 2018 Sep; 25(3):114-118. PubMed ID: 29575979
[TBL] [Abstract][Full Text] [Related]
9. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
10. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
Piggott M; Wilkinson P; Bennett J
J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
[TBL] [Abstract][Full Text] [Related]
11. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
12. Antenatal screening for Down's syndrome.
Wald NJ; Kennard A; Hackshaw A; McGuire A
J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
[TBL] [Abstract][Full Text] [Related]
13. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong.
Lam YH; Ghosh A; Tang MH; Tang LC; Lee CP; Sin SY; Ho PK
Prenat Diagn; 1998 Jun; 18(6):585-89. PubMed ID: 9664604
[TBL] [Abstract][Full Text] [Related]
14. [Prenatal screening: the example of Down's syndrome screening].
Donner C; Daelemans C; Ceysens G
Rev Med Brux; 2015 Sep; 36(4):207-11. PubMed ID: 26591302
[TBL] [Abstract][Full Text] [Related]
15. Comparing outcomes and costs between contingent and combined first-trimester screening strategies for Down's syndrome.
Martín I; Gibert MJ; Aulesa C; Alsina M; Casals E; Bauça JM
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():13-8. PubMed ID: 25827079
[TBL] [Abstract][Full Text] [Related]
16. Maternal serum screening in Ontario using the triple marker test.
Summers AM; Farrell SA; Huang T; Meier C; Wyatt PR
J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
[TBL] [Abstract][Full Text] [Related]
17. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
[TBL] [Abstract][Full Text] [Related]
18. Second trimester screening for Down's syndrome: 7 years experience.
Beaman JM; Goldie DJ
J Med Screen; 2001; 8(3):128-31. PubMed ID: 11678551
[TBL] [Abstract][Full Text] [Related]
19. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
Crossley JA; Aitken DA; Berry E; Connor JM
J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
[TBL] [Abstract][Full Text] [Related]
20. Antenatal screening for Down's syndrome with the quadruple test.
Wald NJ; Huttly WJ; Hackshaw AK
Lancet; 2003 Mar; 361(9360):835-6. PubMed ID: 12642052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
